Pollen Allergy
7
1
1
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
14.3%
1 terminated out of 7 trials
75.0%
-11.5% vs benchmark
57%
4 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Identification of B Regulatory Cells by Flow Cytometry
Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients
Impacts of Nitrogen Deposition in the Natural Environment on Pollen Allergy in Belgium
Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis.
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens
Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy